EP Patent

EP3720442B1 — Inhibiting mutant idh-1

Assigned to Forma Therapeutics Inc · Expires 2022-12-28 · 3y expired

What this patent protects

Patent listed against Rezlidhia.

Drugs covered by this patent

Rezlidhia (OLUTASIDENIB) · Rigel Pharms

Patent Metadata

Patent number: EP3720442B1
Jurisdiction: EP
Classification: —
Expires: 2022-12-28
Drug substance claim: No
Drug product claim: No
Assignee: Forma Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.